Literature DB >> 11258060

[Acute renal failure during severe malaria: physiopathology and therapeutic management. Apropos of 2 cases].

C Duvic1, D Rabar, F Didelot, G Nedelec.   

Abstract

Renal failure secondary to acute tubular necrosis is a common complication of severe Plasmodium falciparum malaria. The purpose of this report is to describe two cases of severe malaria featuring acute renal failure observed in young patients who had failed to comply with chemoprophylaxis. Occurrence of renal failure was delayed four to seven days in relation to the beginning of the malaria attack. Hemodialysis was required in one case. Both patients were successfully treated by quinine perfusion. The main pathophysiology mechanisms underlying acute tubular necrosis are obstruction of capillaries and post-capillary venules by infected red blood cells and activation of monocytes that release cytokines such as tumor necrosis factor. Other nonspecific mechanisms may come into play including hypovolemia, release of catecholamines and subsequent activation of the rennin-angiotensin system, complement activation, and rhabdomyolysis. Acute tubular necrosis is the main renal complication of Plasmodium falciparum malaria but latent forms of acute glomerulonephritis have also been documented. Prognosis is usually favorable depending mainly on early diagnosis and prompt treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11258060

Source DB:  PubMed          Journal:  Med Trop (Mars)        ISSN: 0025-682X


  2 in total

1.  Clinical profile and outcome of pigment-induced nephropathy.

Authors:  Ramanathan Sakthirajan; Jeyachandran Dhanapriya; Arun Varghese; Karunamoorthy Saravanakumar; Thanigachalam Dineshkumar; Thopalan Balasubramaniyan; Natarajan Gopalakrishnan; Anila Abraham Kurien
Journal:  Clin Kidney J       Date:  2017-11-06

2.  Prognostic models for the clinical management of malaria and its complications: a systematic review.

Authors:  Tsi Njim; Bayee Swiri Tanyitiku
Journal:  BMJ Open       Date:  2019-11-26       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.